| Document |
Document Title |
|
WO/2022/066670A1 |
Embodiments of the present invention provide for methods of treating cancer and methods of delivering toll-like receptor (TLR) agonists to solid tumors in the liver using a locoregional therapy through the vasculature. In one aspect, the...
|
|
WO/2022/061663A1 |
Provided are a gRNA targeting CYP4V2 gene and a donor nucleic acid molecule comprising a CYP4V2 gene fragment. Also disclosed in the present application is use of said gRNA and said donor nucleic acid molecule in the preparation of a med...
|
|
WO/2022/063325A1 |
A crystal form of a pyridinylphenyl compound and a preparation method therefor. Use of the crystal form in the preparation of a medicament for treating related diseases is also comprised.
|
|
WO/2022/065404A1 |
Provided is a pharmaceutical composition that can be easily administered in the ear and has the function of retaining a medication and sustainedly releasing the same in the ear. This pharmaceutical composition for otic administration com...
|
|
WO/2022/065436A1 |
The present disclosure pertains to provision of: a tear layer stabilizer; a prophylactic agent, ameliorating agent, and therapeutic agent for corneal epithelial disorders; a prophylactic agent, ameliorating agent, and therapeutic agent f...
|
|
WO/2022/065344A1 |
Provided are: an anti-HTLV-1 antibody for preventing the onset of, or treating, diseases caused by HTLV-1 in a person infected by HTLV-1, or preventing infection in a person not infected by HTLV-1; and a drug containing the antibody as a...
|
|
WO/2022/065848A1 |
The present invention relates to novel Lactobacillus plantarum, Bfidobacterium bifidum, Bifidobacterium longum or mixtures thereof, and a use thereof. Strains or mixtures thereof according to the present invention have excellent Proteoba...
|
|
WO/2022/057778A1 |
The present invention relates to an application of regulation of eye sclera lipid metabolism to inhibit myopia. According to the present invention, discovered is a new mechanism causing myopia, i.e., a close relationship between abnormal...
|
|
WO/2022/061171A1 |
Disclosed herein are methods and compositions for inhibiting and/or reducing pyroptotic cell death in a cell, the composition comprising disulfiram as an active agent and a potentiating ingredient (e.g., tert-Butylhydroquinone (TBHQ)). A...
|
|
WO/2022/059700A1 |
The present invention provides a triazine compound salt that has an aldosterone synthase inhibitory effect and is useful as a medicine, in particular, an agent for preventing or treating primary aldosteronism and the like, a crystal, and...
|
|
WO/2022/058947A1 |
The present invention provides a method of reducing intraocular pressure. In particular, the present invention provides a method of reducing intraocular pressure in a subject to treat a disorder associated with intraocular pressure, the ...
|
|
WO/2022/057234A1 |
A scleral lipid metabolic pathway intervention regulator or an application of a lipid metabolism regulating drug as a drug for inhibiting myopia ametropia and axis oculi extension. By means of a myopia mouse RNA-seq experiment, it is dis...
|
|
WO/2022/061132A1 |
Ophthalmic devices and methods for treating or ameliorating dry eye disease and related symptoms or disorders using such devices are disclosed. In some instances, an ophthalmic device can be configured for placement on the surface of an ...
|
|
WO/2022/058325A1 |
The present invention relates to an oil-in-water emulsion for intravitreal administration, especially injection, comprising an active ingredient, an oil, a mixture of two non-ionic surfactants and water, the emulsion having a droplet siz...
|
|
WO/2022/060984A1 |
The present disclosure provides methods and compositions for modulating the activity of self-associated molecular pattern recognition receptors such as for example, Siglec (sialic-acid-binding immunoglobulin-type lectins) and complement ...
|
|
WO/2022/059800A1 |
The present disclosure relates to bispecific binding molecules against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), including protein sequences, methods for their production, pharmaceut...
|
|
WO/2021/037212A9 |
A composition used for combating metabolic diseases and uses of (or a method for) the composition. The pharmaceutical composition comprises therapeutic agent A or a pharmaceutically acceptable salt thereof; therapeutic agent B or a pharm...
|
|
WO/2022/059736A1 |
The present disclosure provides a composition effective in preventing, suppressing the progression of, or treating diseases associated with endoplasmic reticulum stress such as defective vesicular transport or disorders such as cell deat...
|
|
WO/2022/060251A1 |
The invention relates to pharmacology, and more particularly to the preparation of compositions based on a serotonin receptor antagonist, which can be used in ophthalmology, therapy and geriatrics. Eye drops containing as active ingredie...
|
|
WO/2022/054924A1 |
A purpose of the present invention is to provide a medium suitable for subretinal transplantation of retinal tissue for treating of retinal degenerative disease such as retinitis pigmentosa, and a transplantation composition that contain...
|
|
WO/2022/052454A1 |
The use of an ester group-containing aromatic propionamide compound in the preparation of a medicine for treating dry eye syndrome.
|
|
WO/2022/055796A1 |
Methods and compositions for treatment of impaired visual acuity caused by presbyopia, hyperopia, or astigmatism and methods and compositions for enhancing contrast sensitivity and stereopsis are disclosed. In general, topical compositio...
|
|
WO/2022/056265A1 |
The disclosure provides methods and compositions for the treatment of PDE IV-mediated diseases or conditions, including inflammatory diseases or conditions, using a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
|
|
WO/2021/245539A9 |
The present invention relates to a unit-drug conjugate characterized in that a binding group, which enables binding to another unit-drug conjugate, is additionally connected to the unit-drug conjugate in which a drug is connected to a ta...
|
|
WO/2022/049814A1 |
The present invention addresses the problem of providing a substance that inhibits the growth of herpes simplex virus (HSV) in cells and also providing a medicine or a medicinal composition for treating acute retinal necrosis that compri...
|
|
WO/2022/049259A1 |
The present invention is related to a pigment epithelium-derived factor (PEDF) for use in a method for treatment and/or prevention of dry macular degeneration in a subject, preferably dry age-related macular degeneration, wherein the met...
|
|
WO/2022/049165A1 |
The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
|
|
WO/2022/051728A1 |
The use of Rho Kinase (ROCK1/2) inhibitors for treating or reducing risk of proliferative vitreoretinopathy (PVR) or epiretinal membranes (ERM), e.g., after surgical vitrectomy to treat retinal detachment, and for treatment or reducing r...
|
|
WO/2022/049562A1 |
There is disclosed a compound selected from triazole analogues or pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof is for use in inhibiting a tripartite VAP-A, ORP3 and Rab7 (VOR) protein complex in multicellular org...
|
|
WO/2022/050176A1 |
The present invention provides a composition comprising a novel peptide, and a use thereof (for example, the treatment of a macular hole).
|
|
WO/2022/051294A1 |
The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising admin...
|
|
WO/2022/051537A1 |
Aspects of the disclosure relate to compositions and methods for expressing anti- Vascular endothelial cell growth factor (VEGF) agent in a cell or subject. In some embodiments, the disclosure provides rAAVs comprising a capsid protein (...
|
|
WO/2022/043465A1 |
The invention relates to compounds useful as inhibitors of NO production, especially inhibitors of the inducible NO synthase iNOS expressed by microglia and macrophages. The invention also relates to pharmaceutical compositions comprisin...
|
|
WO/2022/045865A1 |
Disclosed are an anti-VEGF hexameric antibody, and a composition comprising the hexameric antibody.
|
|
WO/2022/042557A1 |
Provided are engineered split Cas12b systems and methods of use thereof. Also provided are compositions comprising one or more components of the engineered split Cas12b systems, as well as engineered cells and non-human animals produced ...
|
|
WO/2022/040909A1 |
Provided are engineered split Cas12b systems and methods of use thereof. Also provided are compositions comprising one or more components of the engineered split Cas12b systems, as well as engineered cells and non-human animals produced ...
|
|
WO/2022/047315A1 |
The present disclosure is directed to compounds, compositions, formulations and methods of use thereof in the treatment and prevention of ocular conditions including cataract and presbyopia.
|
|
WO/2022/047123A1 |
The present disclosure relates to compounds that are capable of upregulating sAPPα and/or stabilizing reticulon-3. The disclosure further relates to methods of treating neurodegenerative diseases and disorders (e.g., Alzheimer's disease).
|
|
WO/2022/042527A1 |
Provided is a composition or kit for obtaining a small-molecule drug which facilitates the regeneration of inner ear and intestinal epithelial tissue. The composition or kit comprises a histone deacetylation inhibitor (e.g., VPA) and an ...
|
|
WO/2022/045502A1 |
The present invention relates to a pharmaceutical composition effective for the prevention or treatment of atopic disease, the pharmaceutical composition containing a Faecalibacterium prausnitzii EB-FPDK11 strain or a culture or dried pr...
|
|
WO/2022/041123A1 |
An application of a sesquiterpene lactone compound in preparing a drug for treating optic neuritis, the sesquiterpene lactone compound and a pharmaceutically acceptable auxiliary material are prepared into a drug. The present study found...
|
|
WO/2022/045836A1 |
The present invention relates to a thiohydantoin derivative and a composition for preventing or treating NADPH oxidase (NOX)-associated diseases comprising same, and can be used to treat NADPH oxidase (NOX)-associated diseases through ex...
|
|
WO/2022/040622A1 |
This invention is directed to a method of preventing ocular neurodegeneration in a subject in need thereof.
|
|
WO/2022/040005A1 |
Disclosed are anti-angiogenic agents that target Pfn1:actin interaction. Also disclosed are compounds for treating ocular diseases or conditions. Further disclosed are compounds for treating cancer.
|
|
WO/2022/037514A1 |
The present invention belongs to the field of pharmaceutical formulations, and relates to a composition comprising a derivative of a wild-type cell-penetrating peptide penetratin and a drug having positive charge under physiological pH c...
|
|
WO/2022/036794A1 |
A method for preparing a single-dose cyclopentolate hydrochloride eye drop. The active ingredient is cyclopentolate hydrochloride, and the auxiliary materials are potassium chloride, boric acid and disodium edetate. No preservatives are ...
|
|
WO/2022/039223A1 |
The present invention addresses the problem of providing a reversible opening agent for a nervous system vascular barrier. To solve the problem, a reversible opening agent for a nervous system vascular barrier is prepared, the reversib...
|
|
WO/2022/037063A1 |
The present disclosure relates to an ophthalmic liposome capable of penetrating a cornea and targeting a retina, a preparation method therefore and an application thereof. The ophthalmic liposome is a liposome which is made of biocompati...
|
|
WO/2022/034909A1 |
The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocula...
|
|
WO/2022/036318A1 |
A plasmid vector comprising one or more heterologous nucleic acids or genes encoding a functional therapeutic protein configured to treat a retinal or ocular includes a human GRK1 promoter and human S/MAR enhancer to express the heterolo...
|
